← Leaderboards
Ryo Nakamura
University Of Southern California
$70,241
Attributed
$70,241
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $34.9K · FY2005–09$50K$37.5K$25K$12.5K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$70,241 · 6
By mechanism
M01$70,241 · 6
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Don J Diamond$24,317,616
- Thomas A Buchanan$121,360,154
- Bijan Najafi$10,971,371
- Arthur W Toga$135,966,223
- Kenneth I. Weinberg$11,172,423
Others in their field
Top investigators on “Grant”
- David R. Weir · University Of Michigan At Ann Arbor$373,949,788
- David Heimbrook · Leidos Biomedical Research, Inc.$341,196,902
- Eric S Lander · Whitehead Institute For Biomedical Res$323,181,457
- Jeffrey P Krischer · University Of South Florida$258,583,867
- Lawrence Corey · Fred Hutchinson Cancer Center$253,286,867
- Barton F Haynes · Duke University$243,251,908
Research focus
GrantComputer Retrieval Of Information On Scientific Projects DatabaseSourceResourcesUnited States National Institutes Of HealthResearch PersonnelInstitutionFundingTransplantationAllogenicBaseEngraftmentGraft-Vs-Host DiseaseHematopoietic Stem Cell TransplantationHomingIncidenceIntegrinsMortality Vital StatisticsPeripheral Blood Stem CellReceptorRecoverySeveritiesSiblingsSite
Grant awards (6)
EFFECT OF DIFFERENTIATION STATUS AND TISSUE SPECIFICATION OF GRAFT T CELLS ON GR$9,277
M01 · FY2009 · RR · contact PI
A PHASE 2 CLINICAL TRIAL TO EVALUATE THE SAFETY, IMMUNOGENICITY AND$1,158
M01 · FY2009 · RR · contact PI
EFFECT OF DIFFERENTIATION STATUS AND TISSUE SPECIFICATION OF GRAFT T CELLS ON GR$13,220
M01 · FY2008 · RR · contact PI
EFFECT OF DIFFERENTIATION STATUS AND TISSUE SPECIFICATION OF GRAFT T CELLS ON GR$34,888
M01 · FY2007 · RR · contact PI
EFFECT OF DIFFERENTIATION STATUS AND TISSUE SPECIFICATION OF GRAFT T CELLS ON$6,532
M01 · FY2006 · RR · contact PI
A PHASE I CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF THE INTRAM$5,166
M01 · FY2005 · RR